International non-profit expands research network to Syracuse to improve
community access to research opportunities
Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, Ichor Research addresses the critical gap in access to cutting-edge clinical research for neurodegenerative diseases that impact millions of elderly Americans.
Ichor Research is an independent research site that specializes in neurodegenerative clinical trials in Syracuse. Through a partnership with Loretto, a non-profit, post-acute healthcare system, Ichor Research has also fostered strong relationships in the community connecting directly with people living in independent living, assisted living, and memory care programs, by providing free memory screenings and brain health educational programming where people live. The unique model and partnership with the fourth largest health system in Central New York, Loretto, allows for interested volunteers to participate in critical research programs in the research clinic, or in their facility-based home.
“GAP is pleased to welcome Ichor Research to our network; Syracuse is fortunate to have such an elite research team in their community,” said GAP President John Dwyer. “At GAP, we are committed to accelerating clinical research for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and we want to help bring clinical trials into communities, like Syracuse, that may not have enjoyed such opportunities. Ichor’s unique model, combining their own site with partnerships that reach those who are already receiving important health services in long term care removes some barriers to access. Their innovative approach to clinical research is a valuable addition to our network.”
Ichor Research joins more than 100 clinical research sites that make up the GAP network, GAP-Net, which improves clinical trial implementation by sharing data and best practices across sites, so trials can proceed more quickly, accelerating neurodegenerative research and improving the participant experience. GAP partners with both private and academic research sites to find cures and treatments for Alzheimer’s and Parkinson’s disease.
There are 6.7 million Americans living with Alzheimer’s disease and that’s expected to more than double to 13.8 million people by 2060. It is currently estimated that 12.7% of New Yorkers are living with dementia[1]. The only way to find treatments and cures for this disease is through clinical trials, and GAP is pleased to welcome Ichor Research in our effort to improve trial design and implementation.
To learn more and find GAP, visit globalalzplatform.org, and to learn more about Ichor Research visit ichorclinic.com.
About the Global Alzheimer’s Platform Foundation (GAP)
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.
[1] https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf